Guggenheim analyst Yatin Suneja raised the firm’s price target on Dianthus (DNTH) to $100 from $92 and keeps a Buy rating on the shares after the company announced tdata from the Phase 2 MaGic trial evaluating the safety and efficacy of claseprubart in adults with acetylcholine receptor antibody positive generalized myasthenia gravis. The data indicate a potential “best-in-class” profile, the analyst tells investors in a research note. Guggenheim believes the readout also de-risks claseprubart in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- EchoStar sells spectrum licenses to SpaceX, StubHub to launch IPO: Morning Buzz
- Promising Phase II Results and Market Potential Drive Buy Rating for Dianthus Therapeutics
- Promising Clinical Data and Strategic Plans Support Buy Rating for Dianthus Therapeutics
- Dianthus gMG data has positive read through to other indications, says Jefferies
- Dianthus price target raised to $72 at Evercore after ‘bull case outcome’